Adjuvant Trials of Toremifene vs Tamoxifen: The European Experience

ONCOLOGY

Volumn 12, Issue 3 SUPPL. 5, 1998, Pages 23-27

  Holli, Kaija ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001782758     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Early Breast Cancer Trialists' Collaboration Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy Lancer 339:1-15, 71-85, 1992
2. Van Leeuvven FE, Benraadt J, Coebergh JWW, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-52, 1994.
3. Rutqvist LE, Johansson H. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87:645-651, 1995
4. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer.occurence of new primaly cancers. Lancet 1:117-20, 1989.
5. Cuzick J, Baum M: Tamoxifen and contralateral breast cancer. Lancer 1 282, 1985
6. Kangas L: Introduction to toremifene Breast Cancer Res Treat 16:3-7, 1990.
7. Valavaara R: Phase II trials with toremifene in advanced breast cancer: A review Breast Cancer Res Treat 16-31-35, 1990.
8. Hamm J, Tormey D, Cohler PC, et al: Phase I study of toremifene in patients with advanced cancer. J Clin Oncol 9:2036-2041, 1991.
9. Vogel C, Shemano I, Schoenfelder J, et al: Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 11:345-350, 1993.
10. Goldhirsch A, Gelber R, Castiglione M, et al: Present and future projects of the International Breast Cancer Study Group. Cancer 74:1139-49, 1994.
11. Machin & Cambell. Statistical Tables for the Design of Clinical Trials, pp 35-37, 94-98. London, Blackwell, 1987.
12. Nayfield SG, Karp JE, Ford LG, et al: Potential role of tamoxifen in prevention of breast cancer J Natl Cancer Inst 83:1450-1459, 1991.
13. Bruning P, Bonfrer J, Hart A, et al: Tamoxifen, serum lipoproteins, and cardiovascular risk. Br J Cancer 58:497-499, 1988.
14. Love RR, Mazess RB, Barden HS, et al: Effect of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992.
15. McDonald CC, Alexander FE, Whyte BW, et al: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br Med J 31:977-980, 1995.
16. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Adjuvant Breast and Bowel Project (NSAPB-14). J Natl Cancer Inst 85:527-537, 1994.
17. Hayes DF, Van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of torernifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556-2566, 1995.
18. Hard GC, Iatropoulus MJ, Jordan K, et al: Major difference in the hepatocarcinogenecity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD (BR) rats. Cancer Res 53:4534-4541, 1993.
19. Hirsimäki P, Hirsimäki Y, Nieminen L, et al: Tamoxifen induces hepatocellular carcinoma in rat liver: A one year study with two antiestrogens. Arch Toxicol 67:49-54, 1993.
20. Saarto T, Blomqvist C, Ehnholm C et al: Antiatherogemc effects of adjuvant antiestrogens: A randomized trial comparing effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 14: 422-429, 1996